Patients

Overview

OncoSec exists for you, the patient.

You drive us to pursue the discovery, development and commercialization of novel products that treat cancer, with a focus on advanced cancers for which there are no adequate therapies today.

Our Intratumoral IL-12 platform is designed to safely and effectively deliver intratumoral IL-12 to a provide long-term presence of a DNA-based therapeutic gene, which activates your immune system to fight the cancer from within.

 

Scientific Publications

Clinical trials of our lead investigational product, TAVO, have demonstrated durable objective responses, extended overall survival and a favorable safety profile. But this is just the beginning. We plan to develop additional product candidates that are designed to activate the patient’s immune system against their own cancer from within.

Currently, we have two clinical trials evaluating the safety and durability of TAVO in combination with pembrolizumab to treat patients who who have progressed or are progressing on an approved checkpoint inhibitor (like pembrolizumab or nivolumab).

View our Scientific Publications

 

Current Clinical Trials

Currently, we have two clinical trials evaluating the safety and durability of TAVO in combination with pembrolizumab to treat patients who who have progressed or are progressing on an approved checkpoint inhibitor (like pembrolizumab or nivolumab).

View our Current Clinical Trials

 

TESTIMONIAL

A Patient’s Perspective

Immunotherapy is changing the way we perceive and treat cancer. Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the power of the immune system to fight disease. We are witnessing the emergence of a new vision within the cancer treatment landscape – one that is having an immediate and powerful impact on cancer patients everywhere.

Melinda Welsh who documented her diagnosis and treatment of squamous cell carcinoma of the head and neck in the Los Angeles Times. The first article discusses her diagnosis and the possibility of enrolling in a clinical trial to test OncoSec’s investigational therapy, TAVO. The second article describes her treatment with TAVO and the results that she experienced. Her story is a poignant reminder of why OncoSec is focused on cancer immunotherapy and developing new treatments for patients. We continue to be inspired by stories like Melinda’s and hope to serve more patients in need. To read Melinda’s testimonials, please visit:

Los Angeles Times – ‘I have terminal cancer. And I’m dying in a yearish.’
Los Angeles Times – I have terminal cancer and I know my friends want to ask, ‘Aren’t you dead yet?’

Learn more about our current clinical trials.Learn more